Diabetic retinopathy (DR) is a severe complication of diabetes mellitus, manifesting as progressive damage to the retinal blood vessels. It represents one of the leading causes of vision impairment and blindness worldwide, significantly impacting patients quality of life. Early detection and management of DR are crucial to prevent irreversible vision loss and improve life quality. Nanotechnology presents a transformative approach to managing DR, promising not only enhanced therapeutic outcomes but also improved patient compliance and quality of life. Ongoing research is essential to address challenges such as large-scale manufacturing, regulatory approval, and long-term safety. Nanomedicine platforms have emerged as transformative tools in the diagnosis and treatment of DR. By leveraging nanoscale materials and technologies, these platforms offer advancements in imaging and therapy, addressing the limitations of conventional approaches. The integration of nanomedicine platforms into the management of DR is paving the way for more effective and personalized treatments while minimizing side effects. By leveraging the unique properties of nanotechnology, these innovations address the limitations of traditional therapies and offer tailored solutions for individual patients. The convergence of nanotechnology and personalized medicine represents a paradigm shift in the treatment of DR, offering safer, patient-centric solutions with fewer side effects and better clinical outcomes. This book chapter emphasizes the advancements, difficulties, and possibilities in creating efficient DR diagnostics and treatments. It also looks at cutting-edge engineering methods that take advantage of our expanding knowledge of nano–bio interactions to produce more effective nanotherapeutics for patients.